Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe stable COPD~Exclusion Criteria:~* History or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium 200 μg once-daily (Type: EXPERIMENTAL): Aclidinium bromide 200 μg once-daily by inhalation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).